Breaking News

Evotec Enters Master Service Agreement with Kazia Therapeutics

Will work together to make EVT801 available to patients globally.

Author Image

By: Charlie Sternberg

Associate Editor

Evotec SE has entered into a licensing and master service agreement with Kazia Therapeutics Limited, an Australian oncology-focused biotechnology company. Under the contract, Evotec will grant Kazia an exclusive worldwide license for research, development and commercialization of Evotec’s oncology project EVT801. EVT801 is a pre-clinical-stage, orally available, small molecule inhibitor of the lymphatic growth factor receptor VEGFR3, originally developed within Evotec’s partnership ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters